FLT3 and acute myeloid leukemia: In order to reduce the rate of mortality and the utilization of healthcare resources, the United Kingdom National Health Service (NHS) made gilteritinib available as an emergency measure to patients aged > 16 y with R/R FLT3 mutant AML starting from April 2020.